|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Lung Cancer
Cancers that begin in the lungs are divided into two major types, non-small cell lung cancer and small cell lung cancer, depending on how the cells look under a microscope. Non-small cell lung cancer is more common than small cell lung cancer, and it generally grows and spreads more slowly. Small cell lung cancer, sometimes called oat cell cancer, is less common, grows more quickly and is more likely to spread to other organs in the body. [Source: www.nihseniorhealth.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Lung Cancer Study CASA404A2302 (ATTRACT 2)
The purpose of this medical research is to study the effects of combining a Novartis investigational drug with docetaxel as a second line treatment, when treating patients with advanced non-small lung cancer. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: This study is anticipated to last approximately 27 months. If the participant meets all the requirements to participate in the study, they will be randomly assigned into 1 of 2 possible groups: Group 1 will receive investigational drug ASA404 plus docetaxel, while Group 2 will receive a placebo (a dummy substance that has no effect on your body) plus docetaxel. Participants will be required to visit the study center to receive a treatment and/or evaluation every 3 weeks. Protocol Number: CASA404A2302 |